nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—Arterial thromboembolism—Thalidomide—leprosy	0.221	0.221	CcSEcCtD
Nafarelin—Embolism arterial—Thalidomide—leprosy	0.147	0.147	CcSEcCtD
Nafarelin—Mental state abnormal—Thalidomide—leprosy	0.0783	0.0783	CcSEcCtD
Nafarelin—Menopause—Thalidomide—leprosy	0.0467	0.0467	CcSEcCtD
Nafarelin—Ascites—Thalidomide—leprosy	0.0233	0.0233	CcSEcCtD
Nafarelin—Transient ischaemic attack—Thalidomide—leprosy	0.021	0.021	CcSEcCtD
Nafarelin—Deep vein thrombosis—Thalidomide—leprosy	0.0174	0.0174	CcSEcCtD
Nafarelin—Myasthenia—Thalidomide—leprosy	0.0169	0.0169	CcSEcCtD
Nafarelin—Seborrhoeic dermatitis—Thalidomide—leprosy	0.0155	0.0155	CcSEcCtD
Nafarelin—Menstrual disorder—Thalidomide—leprosy	0.0155	0.0155	CcSEcCtD
Nafarelin—Interstitial lung disease—Thalidomide—leprosy	0.015	0.015	CcSEcCtD
Nafarelin—Pleural effusion—Thalidomide—leprosy	0.0138	0.0138	CcSEcCtD
Nafarelin—Muscular weakness—Dapsone—leprosy	0.0132	0.0132	CcSEcCtD
Nafarelin—Acne—Thalidomide—leprosy	0.0126	0.0126	CcSEcCtD
Nafarelin—Oliguria—Thalidomide—leprosy	0.0115	0.0115	CcSEcCtD
Nafarelin—Herpes simplex—Thalidomide—leprosy	0.0115	0.0115	CcSEcCtD
Nafarelin—Sinusitis—Dapsone—leprosy	0.0109	0.0109	CcSEcCtD
Nafarelin—Coordination abnormal—Thalidomide—leprosy	0.0108	0.0108	CcSEcCtD
Nafarelin—Pulmonary embolism—Thalidomide—leprosy	0.0106	0.0106	CcSEcCtD
Nafarelin—Rash maculo-papular—Thalidomide—leprosy	0.00963	0.00963	CcSEcCtD
Nafarelin—Gynaecomastia—Thalidomide—leprosy	0.00948	0.00948	CcSEcCtD
Nafarelin—Eye pain—Thalidomide—leprosy	0.00852	0.00852	CcSEcCtD
Nafarelin—Libido decreased—Thalidomide—leprosy	0.00829	0.00829	CcSEcCtD
Nafarelin—Increased appetite—Thalidomide—leprosy	0.00818	0.00818	CcSEcCtD
Nafarelin—Vertigo—Dapsone—leprosy	0.00813	0.00813	CcSEcCtD
Nafarelin—Cerebrovascular accident—Thalidomide—leprosy	0.00785	0.00785	CcSEcCtD
Nafarelin—Disturbance in sexual arousal—Thalidomide—leprosy	0.00763	0.00763	CcSEcCtD
Nafarelin—Affect lability—Thalidomide—leprosy	0.00757	0.00757	CcSEcCtD
Nafarelin—Mood swings—Thalidomide—leprosy	0.00728	0.00728	CcSEcCtD
Nafarelin—Dry skin—Thalidomide—leprosy	0.00705	0.00705	CcSEcCtD
Nafarelin—Muscular weakness—Thalidomide—leprosy	0.00678	0.00678	CcSEcCtD
Nafarelin—Abdominal distension—Thalidomide—leprosy	0.00669	0.00669	CcSEcCtD
Nafarelin—Insomnia—Dapsone—leprosy	0.00668	0.00668	CcSEcCtD
Nafarelin—Weight increased—Thalidomide—leprosy	0.00605	0.00605	CcSEcCtD
Nafarelin—Weight decreased—Thalidomide—leprosy	0.00601	0.00601	CcSEcCtD
Nafarelin—Depression—Thalidomide—leprosy	0.00591	0.00591	CcSEcCtD
Nafarelin—Acute coronary syndrome—Thalidomide—leprosy	0.00584	0.00584	CcSEcCtD
Nafarelin—Myocardial infarction—Thalidomide—leprosy	0.00581	0.00581	CcSEcCtD
Nafarelin—Conjunctivitis—Thalidomide—leprosy	0.00576	0.00576	CcSEcCtD
Nafarelin—Epistaxis—Thalidomide—leprosy	0.00559	0.00559	CcSEcCtD
Nafarelin—Sinusitis—Thalidomide—leprosy	0.00556	0.00556	CcSEcCtD
Nafarelin—Rhinitis—Thalidomide—leprosy	0.00533	0.00533	CcSEcCtD
Nafarelin—Alopecia—Thalidomide—leprosy	0.0047	0.0047	CcSEcCtD
Nafarelin—Vomiting—Dapsone—leprosy	0.00469	0.00469	CcSEcCtD
Nafarelin—Mental disorder—Thalidomide—leprosy	0.00466	0.00466	CcSEcCtD
Nafarelin—Malnutrition—Thalidomide—leprosy	0.00463	0.00463	CcSEcCtD
Nafarelin—Headache—Dapsone—leprosy	0.00462	0.00462	CcSEcCtD
Nafarelin—Tension—Thalidomide—leprosy	0.00454	0.00454	CcSEcCtD
Nafarelin—Dysgeusia—Thalidomide—leprosy	0.00453	0.00453	CcSEcCtD
Nafarelin—Nervousness—Thalidomide—leprosy	0.0045	0.0045	CcSEcCtD
Nafarelin—Nausea—Dapsone—leprosy	0.00439	0.00439	CcSEcCtD
Nafarelin—Vertigo—Thalidomide—leprosy	0.00416	0.00416	CcSEcCtD
Nafarelin—Palpitations—Thalidomide—leprosy	0.00409	0.00409	CcSEcCtD
Nafarelin—Convulsion—Thalidomide—leprosy	0.00401	0.00401	CcSEcCtD
Nafarelin—Arthralgia—Thalidomide—leprosy	0.00394	0.00394	CcSEcCtD
Nafarelin—Myalgia—Thalidomide—leprosy	0.00394	0.00394	CcSEcCtD
Nafarelin—Chest pain—Thalidomide—leprosy	0.00394	0.00394	CcSEcCtD
Nafarelin—Oedema—Thalidomide—leprosy	0.00378	0.00378	CcSEcCtD
Nafarelin—Shock—Thalidomide—leprosy	0.00372	0.00372	CcSEcCtD
Nafarelin—Hyperhidrosis—Thalidomide—leprosy	0.00365	0.00365	CcSEcCtD
Nafarelin—Anorexia—Thalidomide—leprosy	0.0036	0.0036	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Thalidomide—leprosy	0.00344	0.00344	CcSEcCtD
Nafarelin—Insomnia—Thalidomide—leprosy	0.00342	0.00342	CcSEcCtD
Nafarelin—Paraesthesia—Thalidomide—leprosy	0.00339	0.00339	CcSEcCtD
Nafarelin—Dyspnoea—Thalidomide—leprosy	0.00337	0.00337	CcSEcCtD
Nafarelin—Decreased appetite—Thalidomide—leprosy	0.00329	0.00329	CcSEcCtD
Nafarelin—Constipation—Thalidomide—leprosy	0.00323	0.00323	CcSEcCtD
Nafarelin—Urticaria—Thalidomide—leprosy	0.003	0.003	CcSEcCtD
Nafarelin—Asthenia—Thalidomide—leprosy	0.00271	0.00271	CcSEcCtD
Nafarelin—Pruritus—Thalidomide—leprosy	0.00267	0.00267	CcSEcCtD
Nafarelin—Diarrhoea—Thalidomide—leprosy	0.00259	0.00259	CcSEcCtD
Nafarelin—Dizziness—Thalidomide—leprosy	0.0025	0.0025	CcSEcCtD
Nafarelin—Vomiting—Thalidomide—leprosy	0.0024	0.0024	CcSEcCtD
Nafarelin—Rash—Thalidomide—leprosy	0.00238	0.00238	CcSEcCtD
Nafarelin—Dermatitis—Thalidomide—leprosy	0.00238	0.00238	CcSEcCtD
Nafarelin—Headache—Thalidomide—leprosy	0.00237	0.00237	CcSEcCtD
Nafarelin—Nausea—Thalidomide—leprosy	0.00224	0.00224	CcSEcCtD
